By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Biotechnology have been published. According to news reporting from Portland, Oregon, by NewsRx journalists, research stated, "Uveitis is a heterogeneous collection of diseases with polygenic and environmental influences. This heterogeneity presents challenges in trial design and selection of end points."
The news correspondents obtained a quote from the research from the Department of Ophthalmology, "Despite the multitude of causes, therapeutics targeting common inflammatory pathways are effective in treating diverse forms of uveitis. These treatments, including corticosteroids and immunomodulatory agents, although often effective, can have untoward side effects, limiting their utility. The search for drugs with equal or improved efficacy that are safe is therefore paramount. A mechanism-based approach is most likely to yield the future breakthroughs in the treatment of uveitis. We review the literature and provide examples of the nuances of immune regulation and dysregulation that can be targeted for therapeutic benefit. As our understanding of the causes of uveitis grows we will learn how to better apply antibodies designed to block interaction between inflammatory cytokines and their receptors. T-lymphocyte activation can be targeted by blocking costimulatory pathways or inhibiting major histocompatibility complex protein interactions. Furthermore, intracellular downstream molecules from cytokine or other pathways can be inhibited using small molecule inhibitors, which have the benefit of being orally bioavailable. An emerging field is the lipid-mediated inflammatory and regulatory pathways. Alternatively, anti-inflammatory cytokines can be provided by administering recombinant protein, and intracellular 'brakes' of inflammatory pathways can be introduced potentially by gene therapy."
According to the news reporters, the research concluded: "Novel approaches of delivering a therapeutic substance include, but are not limited to, the use of small interfering RNA, viral and nonviral gene therapy, and microparticle or viscous gel sustained-release drug-delivery platforms."
For more information on this research see: The Future of Uveitis Treatment. Ophthalmology, 2014;121(1):365-376. Ophthalmology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Ophthalmology - www.elsevier.com/wps/product/cws_home/620418)
Our news journalists report that additional information may be obtained by contacting P. Lin, Portland VA, Dept. of Ophthalmol, Portland, OR, United States. Additional authors for this research include E.B. Suhler and J.T. Rosenbaum (see also Biotechnology).
Keywords for this news article include: Biotechnology, Oregon, Uveitis, Portland, Treatment, Eye Diseases, Gene Therapy, United States, Ophthalmology, Bioengineering, Uveal Diseases, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC